Collaborative study to establish the first international standard for quantification of anti-HPA-1a

D. Allen, R. Rigsby, H. Bessos, J. Berry, D. W. Wilson, W. Ouwehand, Stanislaw Urbaniak, P. Metcalfe

    Research output: Contribution to journalArticle

    20 Citations (Scopus)


    Background and Objectives This report describes the production of a freeze-dried preparation of pooled human plasma, containing immunoglobulin G (IgG) antibodies against the human platelet antigen 1a (HPA-1a). The material, coded 03/152, is proposed as an International Standard containing 100 arbitrary units of anti-HPA-1a for use in quantitative assays to determine the anti-HPA-1a activity in clinical samples.

    Materials and Methods Plasma samples containing potent anti-HPA-1a were pooled and freeze dried in 1-ml ampoules. In addition, three individual plasma samples were selected which had varying levels of anti-HPA-1a activity. The anti-HPA-1a activity of these three samples was determined by using a variety of quantitative assays with the proposed standard as a reference.

    Results An international collaborative study, which was part of the 2004 ISBT Platelet Immunology Workshop, involved 39 laboratories in 24 countries and showed that the anti-HPA-1a activity in three test samples could be reliably determined by using the proposed standard.

    Conclusions Laboratories can use this standard to measure the anti-HPA-1a activity in patient's samples. Further studies are required to determine the relationship between anti-HPA-1a activity and clinical outcome in patients with neonatal alloimmune thrombocytopenia (NAIT).

    Original languageEnglish
    Pages (from-to)100-104
    Number of pages4
    JournalVox Sanguinis
    Publication statusPublished - 2005


    • anti-HPA-1a
    • NAIT
    • platelet alloantibody detection
    • quantitation
    • ANTI-D
    • 1A

    Cite this

    Allen, D., Rigsby, R., Bessos, H., Berry, J., Wilson, D. W., Ouwehand, W., Urbaniak, S., & Metcalfe, P. (2005). Collaborative study to establish the first international standard for quantification of anti-HPA-1a. Vox Sanguinis, 89, 100-104.